Onco Actu du 24 septembre 2015

	2.5 Etiologie - Gènes
Researchers develop strategy for determining how non-coding gene sequences contribute to disease risk [Massachusetts General Hospital] Dana-Farber/Mass. General-led team uses genome- and epigenome-editing tools to pinpoint disease-causing variants.
	2.6 Etiologie - Environnement
Could Dark Matter Cause Cancer? [MIT Technology Review] Astrophysicists speculate that “mirror” dark matter poses an entirely new form of radiation threat and could cause the mutations that lead to cancer.
	4.9 Dép., diag. & prono. - Sein
DCIS dilemma: Dr. Laura Esserman podcast [HealthNewsReview] She pushes a great deal of rethinking about breast cancer screening and treatment. And DCIS is one of her targets. I talked with Dr. Esserman at the Preventing Overdiagnosis 2015 conference at the National Institutes of Health.
	5.2 Pharma
Pfizer Says It Could Be Leader in Cancer With Many New Drugs [ABC News] Drug giant Pfizer is starting 20 clinical trials this year and more soon after on treatments to conquer cancer as it also seeks to gain leadership in one of the hottest, and most lucrative, areas of medicine.
CTI heads to the FDA with its Baxalta-partnered cancer drug [FierceBiotech] The drug, partnered with Baxalta, is a kinase inhibitor called pacritinib that is designed to treat the rare bone marrow malignancy myelofibrosis. In Phase III results disclosed earlier this year, pacritinib met its main goal by reducing spleen volume by 35% or more in myelofibrosis patients, reversing a deadly effect of the disease
OncoGenex Announces Phase 2 Rainier Results in Previously Untreated Metastatic Pancreatic Cancer [OncoGenex] The addition of apatorsen to ABRAXANE and gemcitabine did not demonstrate a survival benefit compared to ABRAXANE and gemcitabine alone. The study was sponsored and conducted by Sarah Cannon Research Institute (SCRI) and further results will be presented by SCRI at a future medical meeting.
OncoGenex's pancreatic cancer drug found ineffective in study [Reuters] The intravenous drug, apatorsen, when added to Celgene Corp's combination treatment of Abraxane and chemotherapy drug gemcitabine, did not show any survival benefit when compared with the Abraxane combination alone.
Amgen, Allergan say Avastin copycat succeeds in lung cancer study [Reuters] If approved, the Amgen-Allegan drug, ABP 215, would be Amgen's first biosimilar on the market. The company has eight others in development.
	5.2.3 Pharma - économie
Shkreli, Turing, and PhRMA [In the Pipeline] By wrapping ourselves in statements of purpose and noble intentions, we in the R&D-driven part of the drug industry are doing ourselves a disservice. It leaves us unable to distinguish ourselves from obnoxious parasites, outfits like Turing that can, with a straight face, recite the same rationales.
	5.3 Traitements - FDA, EMA,...
Seeing is believing: Making clinical trial statistical data from medical product testing easy to understand [FDA Voice] The collaborators developed a step-by-step process for creating statistical graphs and plots that quickly explain important findings by taking advantage of the way people naturally look for patterns in images, not just in pictures of nature, but also in representations of statistical data.
	5.4 Traitements - Economie
The price isn’t right, but neither is the effect [The Cancer Blog] At the upcoming European Cancer Congress, a study by a UK pharmacologist on how much it costs to make cancer drugs such as imatinib (Glivec) will reveal that Americans in particular are paying hugely more than the manufacturing cost, but Western European prices are also high.
NICE says yes to new class of drug for adults with leukaemia [NICE] The decision follows a preliminary decision earlier this year where NICE asked for the company to provide further information on the cost effectiveness of the drug. Gilead Sciences responded by submitting new economic analyses alongside a simple discount agreement to the list price of idelalisib.
NICE backs Gilead's novel leukaemia drug for NHS use [Pharma Times] The drugmaker responded and agreed to provide Zydelig to the NHS at a reduced price, convincing NICE of its value for money.
How Prescription Drugs Get So Wildly Expensive [WIRED] Perceived value is complicated (it’s economics, after all), but for drugs it pretty much boils down to three things: How many patients the drug will treat, how many similar drugs are on the market, and how much a drug improves a patient’s life.
UK cancer patients being denied drugs due to inflated prices, say experts [The Guardian] Imatinib (Gleevec) – for leukaemia and some other cancers – costs $31,867 in the UK but $28,675 in France and just $8,370 in Russia. Sorafenib (Nexavar), for liver cancer, costs $57,232 in the UK but $49,715 in Spain and $44,543 in France.
	5.6 ESMO
Myriad Genetics Presents New Data on Its Companion Diagnostic and Prostate Cancer Tests at the European Society for Medical Oncology Annual Meeting [Myriad] The presentations include new studies on the myChoice™ HRD and Tumor BRACAnalysis CDx™ companion diagnostic tests and final results from the EMPATHY-P clinical utility study on Prolaris®.
Clovis Oncology Announces Data Presentations at 2015 European Cancer Congress [Clovis Oncology] Rucaparib oral presentation on Tuesday, September 29 to include final outcomes data from full ARIEL2 part 1 population of 206 women with advanced ovarian cancer; Clinical updates on rociletinib in various patient subsets with advanced disease.
AstraZeneca presents advances in oncology research at ECC 2015 with data on AZD9291, durvalumab and LYNPARZA™ (olaparib) [AstraZeneca] 19 oral and poster presentations, including data on AZD9291, durvalumab and olaparib, will provide confirmation and complementary analysis of previously presented results.
	6. Lutte contre les cancers
Bold Blueprint for Precision Medicine Initiative’s Research Cohort [NIH Director's Blog] In addition to the buzz on social media, the Working Group’s framework for the research cohort component of PMI attracted the attention of both mainstream and scientific media.
Here's how to keep clinical trial participants honest (and why that's a big deal) [Retraction Watch] Additional lab tests, creating a clinical trial patient registry, and rewards for honesty are among the advice doled out in this week’s issue of the New England Journal of Medicine for researchers to help avoid the major issue of participants lying to get into clinical trials.
	6.1 Observation
Getting active after a cancer diagnosis may extend life [Reuters] The researchers included 71 studies of physical activity and cancer death risk in the general population or among cancer survivors.
	6.6 Publications
ESMO Announces Christoph Zielinski as Editor-in-Chief of New Open Access Journal [ESMO] ESMO Open is dedicated to publishing high-quality medical research and educational content from all disciplines of oncology, with a focus on innovative clinical and translational cancer research. The first articles will be published in January 2016.
ASCO Publishes First Articles in New Journal of Global Oncology [ASCO] The Journal of Global Oncology was founded to address cancer care, research, and care delivery issues unique to countries and settings with limited health-care resources.
	6.7 DMP, Big Data & applis
ASCO Applauds IOM Report "Improving Diagnosis in Health Care" [ASCO] We are particularly encouraged by IOM’s recommendation to require health IT vendors, by 2018, to meet standards for interoperability among different health IT systems so that effective, efficient, and structured flow of patient information across care settings can be supported.
	6.7.2 Applis
Do we need to rethink regulation for health apps? [PHG Foundation] Although the “quality, safety, or efficacy” of health apps are vital to determine and regulate, there is another side to the control of these apps that the BMJ article does not expand on: the impact they might have on the delivery of healthcare more generally, and how that might need to be managed.
	6.9 Controverses
Parents of Ashya King put him at risk, report says [The Guardian] Last year in the wake of Ashya’s case, a group of leading child cancer doctors wrote to NHS England’s chief executive, Simon Stevens, to express concerns that other families would reject NHS advice and demand treatment abroad which could reduce children’s chances of survival.